13 patents currently held
120 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2027. from the record
Of the 120 now held by other companies, 83 are held via Boehringer Ingelheim International GmbH, and 37 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Mar 2027
Next term end
13
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2029 · High confidence
Also notable
Ends Apr 2030 · High confidence
Also notable
Ends Apr 2028 · High confidence
Also notable
Ends Mar 2027 · High confidence
Also notable
Ends Feb 2037 · High confidence
Also notable
Ends Jun 2040 · High confidence
Also notable
Ends Jun 2027 · High confidence
Also notable
Ends Mar 2030 · High confidence
Capsule Pharmaceutical Dosage Form Comprising a Suspension Formulation of an Indolinone Derivative
US 9,907,756
Cited by 15 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Inhaler and sieve for an inhaler
US 9,010,323
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2030.
Protein Production
US 8,221,999
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
Dry Powder Inhaler
US 7,694,676
The most cited patent in this portfolio, cited by 64 later US patents, top 25% of utility patents granted in 2010 in our data. Protection runs to 2027.
Mammalian Cells for Producing a Secreted Protein
US 10,858,653
Granted 2020. Computed term ends 2037.
ANTI-ANGPT2 Antibodies
US 11,396,539
A family of 5 related applications built on the 2022 grant. Protection runs to 2040.
Regulatory Nucleic Acid Elements
US 9,708,626
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2027.
Substituted 9H-PURIN-2-YL Compounds, Compositions Thereof and Uses Thereof
US 8,404,674
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2030.
Formerly held, still cited
Notable
Ends Oct 2034 · High confidence
Cited by 63 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
held via Boehringer Ingelheim International GmbH - now held by Zealand Pharma A/S
Also notable
Ends Dec 2040 · High confidence
Cited by 18 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2040.
held via Boehringer Ingelheim International GmbH - now held by Ablynx N.V.
Also notable
Ends May 2028 · High confidence
The most cited patent in this portfolio, cited by 67 later US patents, top 25% of utility patents granted in 2006 in our data. Protection runs to 2028.
now held by Sprout Pharmaceuticals, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 3 of the patents on this record were granted since Aug 23, 2026
- 1 term has ended since Aug 23, 2026
- Oct 9 US 10,093,660 Sulfoximine Substituted Quinazolines for Pharmaceutical Compositions · lapsed on the fee record
What they patent
The largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Biomarkers Associated with ANTI-IL-36R Antibody Treatment in Generalized Pustular Psoriasis | 1 in force | to Jan 2045 |
| Substituted Tetrazoles as TRPA1 Inhibitors | 1 in force | to Mar 2043 |
| ANTI-ANGPT2 Antibodies | 1 in force | to Jun 2040 |
| Novel N-(2,2-Difluoroethyl)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | 1 in force | to Sep 2038 |
| Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | 1 in force | to Jan 2038 |
| Mammalian Cells for Producing a Secreted Protein | 1 in force | to Feb 2037 |
| Inhaler and sieve for an inhaler | 1 in force | to Apr 2030 |
| Substituted 9H-PURIN-2-YL Compounds, Compositions Thereof and Uses Thereof | 1 in force | to Mar 2030 |
| Capsule Pharmaceutical Dosage Form Comprising a Suspension Formulation of an Indolinone Derivative | 1 in force | to Jun 2029 |
| Protein Production | 1 in force | to Apr 2028 |
| Regulatory Nucleic Acid Elements | 1 in force | to Jun 2027 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,694,676 | Dry Powder Inhaler In force · High confidence | In force | High confidence | |
| US 9,708,626 | Regulatory Nucleic Acid Elements In force · High confidence | In force | High confidence | |
| US 8,221,999 | Protein Production In force · High confidence | In force | High confidence | |
| US 9,907,756 | Capsule Pharmaceutical Dosage Form Comprising a Suspension Formulation of an Indolinone Derivative In force · High confidence | In force | High confidence | |
| US 8,404,674 | Substituted 9H-PURIN-2-YL Compounds, Compositions Thereof and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,010,323 | Inhaler and sieve for an inhaler In force · High confidence | In force | High confidence | |
| US 8,349,615 | Method for the Optimization of Chromatographic Purification Processes for Biological Molecules In force · High confidence | In force | High confidence | |
| US 10,858,653 | Mammalian Cells for Producing a Secreted Protein In force · High confidence | In force | High confidence | |
| US 10,919,859 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof In force · High confidence | In force | High confidence | |
| US 11,324,724 | Novel N-(2,2-Difluoroethyl)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 120 patents in force now held by others · 7 patents ended · 97 applications pending · 45 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.